The purpose of this study was to evaluate the clinical efficacy and safety of supine daoyin in the treatment of AECOPD.
Chronic obstructive pulmonary disease (COPD) is a chronic progressive disease with high incidence rate, high mortality rate and high disability rate. Among the people over 40, the prevalence rate is 10.1%, while the prevalence rate in China is 13.7%. Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is a major event that affects the natural course of COPD. In particular, most patients with AECOPD have poor prognosis, higher morbidity and mortality, and lower quality of life. Pulmonary rehabilitation can improve the clinical symptoms of AECOPD patients, increase exercise tolerance, delay the decline of lung function, and improve the quality of life. In recent years, the clinical research on the rehabilitation of patients with AECOPD is still in the exploratory stage, which needs to be supported by clear evidence. This is a multicenter, randomized controlled trial to evaluate the clinical efficacy and safety of supine daoyin in the treatment of AECOPD. After admission, the patients were randomly divided into two groups, rehabilitation group and control group, 114 cases in each group. After routine treatment, the patients began to recover when they reached the initial rehabilitation standard, and recovered until they reached the discharge standard. The primary outcomes are the length of hospital stay due to acute exacerbation and clinical symptom score. The secondary outcomes include activities of daily living, dyspnea score, 6-minute walking distance, lower limb muscle strength, mechanical ventilation and quality of life. Safety will also be assessed.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
228
During hospitalization, the rehabilitation group will receive conventional western medicine treatment and supine guidance therapy which consists of training and patient education. They will be evaluated with some tests for the study
The control group will get the western medicine conventional therapy with some additional tests for the study.
The First Affiliated Hospital of Henan University of Chinese
Zhengzhou, Henan, China
RECRUITINGLength of hospital stay due to acute exacerbation
The time from hospitalization to discharge was counted
Time frame: through study completion, an average of 2 weeks
Clinical symptom assessment questionnaire (CCQ)
The Clinical symptom assessment questionnaire (CCQ) is a self-administered questionnaire that measures health-related quality of life. It is an 10-item questionnaire on a 0-6 point scale with higher values indicating greater impact of COPD.
Time frame: Change from baseline CCQ scores at day 3，day 7，day 14
Activities of daily living (Barthel index)
Activities of daily living (ADL): the scale includes 10 items, including 8 items of self-care activities and 2 items of action related activities, with a total score of 100.
Time frame: Change from baseline Barthel index scores at day 3，day 7，day 14
Borg dyspnea score
Borg dyspnea score is is a 10-point (0-10) scale based on the severity of dyspnoea. "0" means no dyspnea perception, "10" means most severe dyspnea perception.
Time frame: Change from baseline Borg dyspnea score at day 3，day 7，day 14
30-second sit-to-stand test
Record the times of sitting and standing test within 30 seconds
Time frame: Change from baseline 30-second sit-to-stand test at day 3，day 7，day 14
Mechanical ventilation
The number of patients using noninvasive or invasive mechanical ventilation during the study period was counted
Time frame: through study completion, an average of 2 weeks
Li jiansheng, doctor
CONTACT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
6 Minutes Walking Distance Test (6MWD)
The 6-minute walking distance of the two groups was calculated
Time frame: Change from baseline 6MWD test at day 7，day 14
St. George's Respiratory Questionnaire（SGRQ）
The St. George's Respiratory Questionnaire (SGRQ) scores will be used to evaluate quality of life with a total score of 0-100. The higher scores will indicate the worse outcomes.
Time frame: Change from baseline SGRQ scores at day 3，day 7，day 14
The modified COPD Patient-Reported Outcome scale (mCOPD-PRO)
The modified COPD Patient-Reported Outcome scale (mCOPD-PRO) will be used to assess quality of life. The mCOPD-PRO contains 27 items in three domains. mCOPD-PRO scores range from 0 to 4 with a decrease in score showing higher health status.
Time frame: Change from baseline mPRO-COPD scores at day 3，day 7，day 14
The modified Effectiveness Satisfaction Questionnaire for COPD (mESQ-COPD)
The modified Effectiveness Satisfaction Questionnaire for COPD (mESQ-COPD) will be used to assess treatment satisfaction. The mESQ-COPD contains 19 items in four domains. mESQ-COPD scores range from 0 to 4 with a decrease in score showing higher treatment satisfaction.
Time frame: Change from baseline mESQ-COPD scores at day 3，day 7，day 14